HEALTH

• Moderna and Merck announced on August 19, 2026, that their personalized mRNA vaccine, intismeran autogene, successfully passed a late-stage clinical trial. • The vaccine was used in combination with the immunotherapy drug Keytruda to effectively reduce the recurrence of melanoma, a form of skin cancer. • This milestone represents a significant breakthrough in oncology, demonstrating the potential for mRNA technology to transform both cancer treatment and prevention.

• The rise of GLP-1 weight-loss drugs is influencing the food industry, prompting restaurants to adjust both food and beverage offerings to meet changing consumer habits. • Health officials are tracking a growing outbreak of Cyclosporiasis, which has already resulted in hundreds of hospitalizations across the United States. • A thyroid medication was recently recalled due to concerns that the drug may be superpotent, potentially triggering dangerous side effects for patients.

• Preparations for the 2026-2027 vaccine season are underway, marked by major industry acquisitions and a critical upcoming FDA panel vote. • New data on influenza vaccine effectiveness is being analyzed, though experts warn that real-time tracking of variant evolution is becoming increasingly difficult. • Dr. Jill Roberts of the University of South Florida attributes this data gap to reduced government surveillance staffing and significant cuts to academic research funding.

• A New York Times report highlights that the rise of cheap, potent synthetic drugs like fentanyl has significantly increased dealer profits and heightened risks for drug users. • A cross-sectional study published in JAMA Network Open suggests that the way patients phrase messages in patient portals may trigger clinician bias. • This bias in triage responses could lead to significant care disparities for patients based on their communication style.

• Merck and Moderna reported that their experimental cancer "vaccine" successfully slowed the progression of melanoma. • The report also examines and dissects the trial strategies employed by Chinese researchers following recent patient deaths. • These developments highlight critical advancements in personalized immunotherapy and the ongoing scrutiny of clinical trial safety protocols.

• Researchers at UC San Diego School of Medicine found that a 4-day course of a mycelium-based fungal supplement reduced adverse reactions in COVID-naive vaccine recipients. • According to a double-blind, placebo-controlled trial (NCT04951336) published in BMC Immunology, the supplement also helped sustain antibody levels for up to 6 months. • These findings are significant as they could improve vaccine tolerability and help reduce vaccine hesitancy among the general population.

• President Trump and HHS Secretary Kennedy have implemented sweeping health policy reforms over the last 555 days to combat the chronic disease epidemic and revitalize public health. • Key achievements include securing pledges from insurers, medical societies, and providers to improve national behavioral health quality and best practices. • The FDA has announced a strategic plan to phase out animal testing requirements for monoclonal antibodies and various other drugs.

• A multinational study published in The Lancet Infectious Diseases reveals that drug-resistant hospital infections in Asia are substantial and likely underestimated, especially in low- and middle-income countries. • The report highlights a critical public health crisis where antimicrobial resistance complicates treatment and increases mortality rates across the region. • Other recent health data indicates varying vaccination rates based on race and education, while a separate analysis of 1.4 million records links vaccination to a lower risk of head and neck tumors.

• Pulnovo Medical has enrolled the first two U.S. patients in its PULSE-LHD clinical trial at Henry Ford Hospital in Detroit. • The trial is conducted under an FDA Investigational Device Exemption (IDE) to evaluate pulmonary artery denervation for treating pulmonary hypertension associated with left heart disease. • This study is significant as it tests a novel medical device approach to managing complex heart failure and pulmonary hypertension conditions.

• The Australian Medical Association (AMA) has issued a new position statement urging specialist medical colleges to increase the transparency of their fees. • This move aims to provide patients with clearer information regarding the costs associated with specialist medical services. • The initiative matters as it addresses growing concerns over healthcare affordability and the lack of pricing clarity for patients navigating the system.

• Medical experts are highlighting that knee osteoarthritis is not inevitable and can be prevented or managed through specific everyday lifestyle adjustments. • Researchers have identified a metabolic pathway involving the conversion of isoleucine and valine into propionyl-CoA that may contribute to hormone therapy resistance in prostate cancer. • This discovery suggests that drugs targeting these specific enzymes or controlled dietary strategies could potentially overcome treatment resistance in cancer patients.

• Mark Orwig participated in a clinical trial for an mRNA vaccine designed to prevent the recurrence of melanoma after surgical tumor removal. • The treatment targets lingering cancer cells that often remain in the body post-surgery, which typically lead to the disease returning. • Scientists believe this personalized mRNA approach could revolutionize cancer care by transforming how doctors treat high-risk patients.

• COVID-19 is seeing a resurgence in the United States, prompting renewed discussions on the necessity of fall vaccines and the risks of repeat infections. • Recent medical research highlights critical interventions, including a Sept. 1, 2025, JAMA study on germicidal UV light to reduce respiratory infections in long-term care facilities. • Experts emphasize the importance of improving shared indoor air quality and understanding the acute and post-acute sequelae associated with SARS-CoV-2 reinfection.

• A new analysis published in PLOS Digital Health reveals that of the 1,357 AI-based medical devices authorized by the FDA, only three were tested to determine if they actually improve patient health outcomes. • The study found a significant lack of rigorous validation, noting that only 34 of the cleared devices were linked to registered clinical trials. • This gap highlights a critical regulatory concern, as the vast majority of AI tools are entering patient care without evidence that they provide tangible clinical benefits.

• Scientists in India have developed a "smart" cancer drug designed to target tumors more precisely, potentially reducing the reliance on traditional chemotherapy. • In a separate study published in the American Journal of Cardiovascular Drugs, researchers from the University of East Anglia and Norfolk and Norwich University Hospital analyzed data from nine studies. • This cardiovascular research involved over 480,000 participants aged 35 to 84, including healthy adults and those with existing heart disease, followed for a median of 14 years.

• NanoViricides has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 Oral Gummies. • The trial is being conducted under the leadership of Professor Katoto, with Patrick, a Fogarty Fellow and member of the Institute for Health Metrics, involved in the process. • This development is significant as it advances the testing of NV-387, moving the drug candidate closer to potential commercialization and clinical use.

• Recent health updates highlight a shift toward less aggressive therapy options for treating prostate cancer to reduce patient side effects. • Meta glasses are being integrated into hospital settings to explore how augmented reality can assist medical professionals in clinical environments. • The "Morning Rounds" report also covers developments regarding an Ebola vaccine as part of its broader health news coverage.

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.